106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia

Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation Methods: Secondary analysis of an anonymized database of sixty one patients with T2DM, evaluated hba1c, fasting glucose, TDID, and hypoglycemic episodes, Before, 3 and 6 months after IDEGLIRA. Weight could not me measured due to teleconsultation limitation. Performed univariated analysis of cuantitative viariables, bivariated analysis of clinical variables pre and post ideglira treatment. patients received tele-education by a diabetes educator for insulin titration Results: 59% women, previos IDEGLIRA: 45.9% used 1 oral antidiabetic 29.5% used 2 and 55.7% used oral antidiabetics plus insulin. 54.1% used basal insulin regimen, the mean TDID was 38 units previous ideglira use, and 26 U after use (p= 0.0001). The mean for HBA1c levels was 8.44% (SD:1.4) prior to the use of ideglira, 7.78% (SD: 0.9) at 3rd month and 7.4% (SD:0.91) at 6th month. Significant differences were found when comparing zero months to three months (p= 0.01), and zero to six months (p= 0.0001), and comparing 3 and 6 months (p=0.003). Goal of hba1c